胃癌患者血清HER2-ECD水平的评估
Evaluation of serum HER2-ECD levels in patients with gastric cancer.
作者信息
Oyama Katsunobu, Fushida Sachio, Tsukada Tomoya, Kinoshita Jun, Watanabe Toshifumi, Shoji Masatoshi, Nakanuma Shinichi, Okamoto Koichi, Sakai Seisho, Makino Isamu, Nakamura Keishi, Hayashi Hironori, Inokuchi Masafumi, Nakagawara Hisatoshi, Miyashita Tomoharu, Tajima Hidehiro, Takamura Hiroyuki, Ninomiya Itasu, Kitagawa Hirohisa, Fujimura Takashi, Tajiri Ryousuke, Ooi Akishi, Ohta Tetsuo
机构信息
Department of Gastroenterologic Surgery, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan,
出版信息
J Gastroenterol. 2015 Jan;50(1):41-5. doi: 10.1007/s00535-014-0941-3. Epub 2014 Feb 21.
BACKGROUND
Determination of the human epidermal growth factor receptor 2 (HER2) status of gastric cancer patients is indispensable in clinical practice. However, the clinical value of serum HER2-extracellular domain (ECD) in gastric cancer has not yet been defined.
METHODS
The serum level of HER2-ECD was measured using the chemiluminescence immunoassay method, and its relationship with tissue HER2 status and clinicopathologic features was examined. Transition of serum HER2-ECD level was examined in patients during chemotherapy to clarify the correlation between changes in the level of HER2-ECD in serum and response to chemotherapy.
RESULTS
A total of 150 gastric cancer patients were enrolled in this study; changes in HER2-ECD level were examined in 36 of these patients during chemotherapy. Serum levels of HER2-ECD ranged from 4.8 to 180.0 ng/ml (median 9.2 ng/ml) and were positive (cutoff value 15.2 ng/ml) in ten patients (6.7 %). There was a significant correlation between serum HER2-ECD level and tissue HER2 status (P < 0.001); however, no correlation with TNM stage was found. Change in serum HER2-ECD level during chemotherapy was significantly correlated with response to chemotherapy in patients with HER2-positive tumor tissue.
CONCLUSIONS
Serum HER2-ECD is a potential biomarker of gastric cancer and could be used as a diagnostic marker with regard to tissue HER2 status, and also as a monitoring marker in relation to response to chemotherapy.
背景
确定胃癌患者的人表皮生长因子受体2（HER2）状态在临床实践中不可或缺。然而，血清HER2细胞外结构域（ECD）在胃癌中的临床价值尚未明确。
方法
采用化学发光免疫分析法测定血清HER2-ECD水平，并检测其与组织HER2状态及临床病理特征的关系。在化疗期间检测患者血清HER2-ECD水平的变化，以阐明血清中HER2-ECD水平变化与化疗反应之间的相关性。
结果
本研究共纳入150例胃癌患者；其中36例患者在化疗期间检测了HER2-ECD水平的变化。血清HER2-ECD水平为4.8至180.0 ng/ml（中位数9.2 ng/ml），10例患者（6.7%）呈阳性（临界值15.2 ng/ml）。血清HER2-ECD水平与组织HER2状态之间存在显著相关性（P < 0.001）；然而，未发现与TNM分期相关。HER2阳性肿瘤组织患者化疗期间血清HER2-ECD水平的变化与化疗反应显著相关。
结论
血清HER2-ECD是胃癌的潜在生物标志物，可作为组织HER2状态的诊断标志物，也可作为化疗反应的监测标志物。
Zotero 插件